|
2015 Journal Article Acquired <i>BRAF</i> inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsJohnson, Douglas B., Menzies, Alexander M., Zimmer, Lisa, Eroglu, Zeynep, Ye, Fei, Zhao, Shilin, Rizos, Helen, Sucker, Antje, Scolyer, Richard A., Gutzmer, Ralf, Gogas, Helen, Kefford, Richard F., Thompson, John F., Becker, Juergen C., Berking, Carola, Egberts, Friederike, Loquai, Carmen, Goldinger, Simone M., Pupo, Gulietta M., Hugo, Willy, Kong, Xiangju, Garraway, Levi A., Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S., Long, Georgina V. and Schadendorf, Dirk (2015). Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 51 (18), 2792-2799. doi: 10.1016/j.ejca.2015.08.022 |
|
2015 Journal Article Genomic correlates of response to CTLA-4 blockade in metastatic melanomaVan Allen, Eliezer M., Miao, Diana, Schilling, Bastian, Shukla, Sachet A., Blank, Christian, Zimmer, Lisa, Sucker, Antje, Hillen, Uwe, Foppen, Marnix H. Geukes, Goldinger, Simone M., Utikal, Jochen, Hassel, Jessica C., Weide, Benjamin, Kaehler, Katharina C., Loquai, Carmen, Mohr, Peter, Gutzmer, Ralf, Dummer, Reinhard, Gabriel, Stacey, Wu, Catherine J., Schadendorf, Dirk and Garraway, Levi A. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 350 (6257), 207-211. doi: 10.1126/science.aad0095 |
|
2015 Journal Article Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?Mangana, Joanna, Cheng, Phil F., Schindler, Katja, Weide, Benjamin, Held, Ulrike, Frauchiger, Anna L., Romano, Emanuella, Kaehler, Katharina C., Rozati, Sima, Rechsteiner, Markus, Moch, Holger, Michielin, Olivier, Garbe, Claus, Hauschild, Axel, Hoeller, Christoph, Dummer, Reinhard and Goldinger, Simone M. (2015). Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. Plos One, 10 (10) e0139438. doi: 10.1371/journal.pone.0139438 |
|
2015 Journal Article Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanomaMatsushita, Shigeto, Kraehenbuehl, Lukas, Otsuka, Atsushi, Mihic-Probst, Daniela, Cheng, Phil, Dummer, Reinhard and Goldinger, Simone M. (2015). Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma. Journal of Dermatology, 42 (9), 927-928. doi: 10.1111/1346-8138.12964 |
|
2015 Journal Article Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialRibas, Antoni, Puzanov, Igor, Dummer, Reinhard, Schadendorf, Dirk, Hamid, Omid, Robert, Caroline, Hodi, F. Stephen, Schachter, Jacob, Pavlick, Anna C., Lewis, Karl D., Cranmer, Lee D., Blank, Christian U., O'Day, Steven J., Ascierto, Paolo A., Salama, April K. S., Margolin, Kim A., Loquai, Carmen, Eigentler, Thomas K., Gangadhar, Tara C., Carlino, Matteo S., Agarwala, Sanjiv S., Moschos, Stergios J., Sosman, Jeffrey A., Goldinger, Simone M., Shapira-Frommer, Ronnie, Gonzalez, Rene, Kirkwood, John M., Wolchok, Jedd D., Eggermont, Alexander ... Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16 (8), 908-918. doi: 10.1016/S1470-2045(15)00083-2 |
|
2015 Conference Publication Radio Sensitization through BRAF Inhibitors- Mechanism and Frequency of Toxicities in Melanoma patientsHecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., Forschner, A., Clemens, P., Grabenbauer, G., Mueller-Brenne, T., Bauch, J., Eich, H. T., Grabbe, S., Schadendorf, D., Schuler, G., Keikavoussi, P., Semrau, S., Fietkau, R., Distel, L. V. and Heinzerling, L. (2015). Radio Sensitization through BRAF Inhibitors- Mechanism and Frequency of Toxicities in Melanoma patients. 21st Annual Meeting of the German-Society-for-Radiation-Oncology, Hamburg Germany, Jun 25-28, 2015. MUNICH: URBAN & VOGEL. |
|
2015 Journal Article Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patientsHecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., Forschner, A., Clemens, P., Grabenbauer, G., Mueller-Brenne, T., Bauch, J., Eich, H. T., Grabbe, S., Schadendorf, D., Schuler, G., Keikavoussi, P., Semrau, S., Fietkau, R., Distel, L. V. and Heinzerling, L. (2015). Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Annals of Oncology, 26 (6), 1238-1244. doi: 10.1093/annonc/mdv139 |
|
2015 Conference Publication Association of PD-L1 expression in melanoma with response and prognosis to ipilimumabBrueggemann, Caroline, Weide, Benjamin, Goldinger, Simone M., Konrad, Andreas, Erdmann, Michael, Schadendorf, Dirk, Croner, Roland S., Kraehenbuehl, Lukas, Kaehler, Katharina C., Hafner, Christian, Leisgang, Waltraud, Kiesewetter, Franklin, Dummer, Reinhard, Schuler, Gerold, Stuerzl, Michael and Heinzerling, Lucie (2015). Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. |
|
2015 Conference Publication A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphomaGoldinger, Simone M., Gobbi, Sharon, Ding, Michelle, Frauchiger, Anna Lisa, Fink-Puches, Regina, Klemke, Claus-Detlev, Dreno, Brigitte, Bagot, Martine, Assaf, Chalid and Dummer, Reinhard (2015). A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. |
|
2015 Conference Publication Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patientsGoldinger, Simone M., Mangana, Joanna, Frauchiger, Anna L., Kaufmann, Corina, Held, Ulrike, Von Moos, Roger, Romano, Emanuela, Michielin, Olivier, Levesque, Mitchell Paul and Dummer, Reinhard (2015). Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. |
|
2015 Conference Publication Efficacy and safety of oral alitretinoin in oral mucosal lichen planus-results of a prospective trialKunz, Michael, Urosevic-Maiwald, Mirjana, Cozzio, Antonio, Dippel, Michaela, Dreier, Jil, French, Lars E., Goldinger, Simone, Guenova, Emmanuella, Jenni, Daniella, Kamarachev, Jivko, Mangana, Johanna and Dummer, Reinhard (2015). Efficacy and safety of oral alitretinoin in oral mucosal lichen planus-results of a prospective trial. NEW YORK: MOSBY-ELSEVIER. |
|
2015 Conference Publication Systemic treatments in melanoma influence the accessibility of the immune system to the tumor: A retrospective histopathological investigationKraehenbuehl, L., Goldinger, S. M., Matsushita, S., Amann, V. C., Kempf, W., Levesque, M. P. and Dummer, R. (2015). Systemic treatments in melanoma influence the accessibility of the immune system to the tumor: A retrospective histopathological investigation. HOBOKEN: WILEY-BLACKWELL. |
|
2015 Journal Article Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitorGalliker, Nadja A., Murer, Carla, Kamarashev, Jivko, Dummer, Reinhard and Goldinger, Simone M. (2015). Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. European Journal of Dermatology, 25 (2), 177-180. doi: 10.1684/ejd.2014.2512 |
|
2015 Journal Article Curing advanced melanoma by 2025Dummer, Reinhard, Goldinger, Simone M., Paulitschke, Verena and Levesque, Mitchell P. (2015). Curing advanced melanoma by 2025. Current Opinion in Oncology, 27 (2), 125-127. doi: 10.1097/CCO.0000000000000168 |
|
2015 Journal Article A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanomaGoldinger, Simone M., Rinderknecht, Jeannine, Dummer, Reinhard, Kuhn, Felix Pierre, Yang, Kuo-Hsiung, Lee, Lucy, Ayala, Ruben C., Racha, Jagdish, Geng, Wanping, Moore, David, Liu, Mei, Joe, Andrew K., Bazan, Selby Patricia Gil and Grippo, Joseph F. (2015). A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacology Research & Perspectives, 3 (2) e00113. doi: 10.1002/prp2.113 |
|
2015 Journal Article Methylation-dependent <i>SOX9</i> expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanomaCheng, Phil F., Shakhova, Olga, Widmer, Daniel S., Eichhoff, Ossia M., Zingg, Daniel, Frommel, Sandra C., Belloni, Benedetta, Raaijmakers, Marieke I. G., Goldinger, Simone M., Santoro, Raffaella, Hemmi, Silvio, Sommer, Lukas, Dummer, Reinhard and Levesque, Mitchell P. (2015). Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology, 16 42. doi: 10.1186/s13059-015-0594-4 |
|
2014 Journal Article Basal cell carcinomas in a tertiary referral centre: a systematic analysisDreier, J., Cheng, P. F., Alleman, I. Bogdan, Gugger, A., Hafner, J., Tschopp, A., Goldinger, S. M., Levesque, M. P. and Dummer, R. (2014). Basal cell carcinomas in a tertiary referral centre: a systematic analysis. British Journal of Dermatology, 171 (5), 1066-1072. doi: 10.1111/bjd.13217 |
|
2014 Journal Article Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous <i>t</i>-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome)Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E. A., Rozati, S., Eggmann, N., Goldinger, S. M., Hutchinson, K., Geskin, L., Illidge, T. M., Giuliano, E., Elder, J. and Kim, Y. H. (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome). Annals of Oncology, 25 (9), 1807-1812. doi: 10.1093/annonc/mdu231 |
|
2014 Conference Publication Association of leukocyte counts and adverse events in BRAF inhibitor-treated patientsCosgarea, I., Sondermann, W., Livingstone, E., Griewank, K., Weide, B., Loquai, C., Hassel, J., Kaehler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Schadendorf, D., Zimmer, L. and Schilling, B. (2014). Association of leukocyte counts and adverse events in BRAF inhibitor-treated patients. HOBOKEN: WILEY-BLACKWELL. |
|
2014 Conference Publication Immunreactivity for CTLA-4 in anterior pituitary gland cells and neutrophils suggest antibody dependent cytotoxicity to trigger Ipilimumab induced hypophysitisBjasch, D., Maggio, E. Marquez, Fitsche, A., Moch, H., Goldinger, S. M., Dummer, R. and Mihic-Probst, D. (2014). Immunreactivity for CTLA-4 in anterior pituitary gland cells and neutrophils suggest antibody dependent cytotoxicity to trigger Ipilimumab induced hypophysitis. NEW YORK: SPRINGER. |
